Search

Your search keyword '"Locatelli, Marco"' showing total 9 results
Start Over Author "Locatelli, Marco" Journal cancers
9 results on '"Locatelli, Marco"'

1. Surgery vs. Radiosurgery for Patients with Localized Metastatic Brain Disease: A Systematic Review with Meta-Analysis of Randomized Controlled Trials

Author

Fiore, Giorgio, primary, Tariciotti, Leonardo, additional, Bertani, Giulio Andrea, additional, Gagliano, Dario, additional, D’Ammando, Antonio, additional, Ampollini, Antonella Maria, additional, Schisano, Luigi, additional, Borsa, Stefano, additional, Pluderi, Mauro, additional, Locatelli, Marco, additional, and Caroli, Manuela, additional

Published
2023
Full Text
View/download PDF

2. A β-Arrestin 2-Biased Dopamine Receptor Type 2 (DRD2) Agonist Is More Efficacious Than Cabergoline in Reducing Cell Proliferation in PRL-Secreting but Not in Non-Functioning Pituitary Tumor Cells

Author

Di Muro, Genesio, primary, Mangili, Federica, additional, Esposito, Emanuela, additional, Barbieri, Anna Maria, additional, Catalano, Rosa, additional, Treppiedi, Donatella, additional, Marra, Giusy, additional, Nozza, Emma, additional, Lania, Andrea G. A., additional, Ferrante, Emanuele, additional, Locatelli, Marco, additional, Arosio, Maura, additional, Peverelli, Erika, additional, and Mantovani, Giovanna, additional

Published
2023
Full Text
View/download PDF

4. A Frailty-Adjusted Stratification Score to Predict Surgical Risk, Post-Operative, Long-Term Functional Outcome, and Quality of Life after Surgery in Intracranial Meningiomas

Author

Tariciotti, Leonardo, primary, Fiore, Giorgio, additional, Carapella, Sara, additional, Remore, Luigi Gianmaria, additional, Schisano, Luigi, additional, Borsa, Stefano, additional, Pluderi, Mauro, additional, Canevelli, Marco, additional, Marfia, Giovanni, additional, Caroli, Manuela, additional, Locatelli, Marco, additional, and Bertani, Giulio, additional

Published
2022
Full Text
View/download PDF

5. P720R USP8 Mutation Is Associated with a Better Responsiveness to Pasireotide in ACTH-Secreting PitNETs

Author

Treppiedi, Donatella, primary, Marra, Giusy, additional, Di Muro, Genesio, additional, Esposito, Emanuela, additional, Barbieri, Anna Maria, additional, Catalano, Rosa, additional, Mangili, Federica, additional, Bravi, Francesca, additional, Locatelli, Marco, additional, Lania, Andrea Gerardo, additional, Ferrante, Emanuele, additional, Indirli, Rita, additional, Nozza, Emma, additional, Arlati, Federico, additional, Spada, Anna, additional, Arosio, Maura, additional, Mantovani, Giovanna, additional, and Peverelli, Erika, additional

Published
2022
Full Text
View/download PDF

6. Effects of Metformin as Add-On Therapy against Glioblastoma: An Old Medicine for Novel Oncology Therapeutics

Author

Guarnaccia, Laura, primary, Navone, Stefania E., additional, Masseroli, Matteo M., additional, Balsamo, Melissa, additional, Caroli, Manuela, additional, Valtorta, Silvia, additional, Moresco, Rosa M., additional, Campanella, Rolando, additional, Schisano, Luigi, additional, Fiore, Giorgio, additional, Galiano, Valentina, additional, Garzia, Emanuele, additional, Appiani, Giuseppe C., additional, Locatelli, Marco, additional, Riboni, Laura, additional, and Marfia, Giovanni, additional

Published
2022
Full Text
View/download PDF

7. Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma

Author

Guarnaccia, Laura, primary, Marfia, Giovanni, additional, Masseroli, Matteo Maria, additional, Navone, Stefania Elena, additional, Balsamo, Melissa, additional, Caroli, Manuela, additional, Valtorta, Silvia, additional, Moresco, Rosa Maria, additional, Campanella, Rolando, additional, Garzia, Emanuele, additional, Riboni, Laura, additional, and Locatelli, Marco, additional

Published
2021
Full Text
View/download PDF

8. Genetic Profiling of a Cohort of Italian Patients with ACTH-Secreting Pituitary Tumors and Characterization of a Novel USP8 Gene Variant

Author

Treppiedi, Donatella, primary, Barbieri, Anna Maria, additional, Di Muro, Genesio, additional, Marra, Giusy, additional, Mangili, Federica, additional, Catalano, Rosa, additional, Esposito, Emanuela, additional, Ferrante, Emanuele, additional, Serban, Andreea Liliana, additional, Locatelli, Marco, additional, Lania, Andrea Gerardo, additional, Spada, Anna, additional, Arosio, Maura, additional, Peverelli, Erika, additional, and Mantovani, Giovanna, additional

Published
2021
Full Text
View/download PDF

9. Frontiers in Anti-Cancer Drug Discovery: Challenges and Perspectives of Metformin as Anti-Angiogenic Add-On Therapy in Glioblastoma.

Author

Guarnaccia, Laura, Marfia, Giovanni, Masseroli, Matteo Maria, Navone, Stefania Elena, Balsamo, Melissa, Caroli, Manuela, Valtorta, Silvia, Moresco, Rosa Maria, Campanella, Rolando, Garzia, Emanuele, Riboni, Laura, and Locatelli, Marco

Subjects
DRUG efficacy, GLIOMAS, ANTINEOPLASTIC agents, PATHOLOGIC neovascularization, METFORMIN, DRUG development, COMBINED modality therapy, PATIENT safety, PHARMACODYNAMICS
Abstract

Simple Summary: Glioblastoma is the most aggressive primary brain tumor, with the highest incidence and the worst prognosis. Life expectancy from diagnosis remains dismal, at around 15 months, despite surgical resection and treatment with radiotherapy and chemotherapy. Given the aggressiveness of the tumor and the inefficiency of the treatments adopted to date, the scientific research investigates innovative therapeutic approaches. Importantly, angiogenesis represents one of the main features of glioblastoma, becoming in the last few years a major candidate for target therapy. Metformin, a well-established therapy for type 2 diabetes, offered excellent results in preventing and fighting tumor progression, particularly against angiogenic mechanisms. Therefore, the purpose of this review is to summarize and discuss experimental evidence of metformin anti-cancer efficacy, with the aim of proposing this totally safe and tolerable drug as add-on therapy against glioblastoma. Glioblastoma is the most common primitive tumor in adult central nervous system (CNS), classified as grade IV according to WHO 2016 classification. Glioblastoma shows a poor prognosis with an average survival of approximately 15 months, representing an extreme therapeutic challenge. One of its distinctive and aggressive features is aberrant angiogenesis, which drives tumor neovascularization, representing a promising candidate for molecular target therapy. Although several pre-clinical studies and clinical trials have shown promising results, anti-angiogenic drugs have not led to a significant improvement in overall survival (OS), suggesting the necessity of identifying novel therapeutic strategies. Metformin, an anti-hyperglycemic drug of the Biguanides family, used as first line treatment in Type 2 Diabetes Mellitus (T2DM), has demonstrated in vitro and in vivo antitumoral efficacy in many different tumors, including glioblastoma. From this evidence, a process of repurposing of the drug has begun, leading to the demonstration of inhibition of various oncopromoter mechanisms and, consequently, to the identification of the molecular pathways involved. Here, we review and discuss metformin's potential antitumoral effects on glioblastoma, inspecting if it could properly act as an anti-angiogenic compound to be considered as a safely add-on therapy in the treatment and management of glioblastoma patients. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results